Guardant Transforms Detection for Early-Stage Colo-rectal Cancer

Despite multiple screening modalities for colorectal cancer (CRC), screening rates remain stubbornly low, leaving many cancers undetected until cancer is advanced and, therefore, less successful, and far more costly. The less-invasive Guardant blood test that can accurately detect CRC represents a significant opportunity to overcome some of the known challenges with patient adherence, playing a critical role in improving screening rates and saving lives.